Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Blood Glucose Testing For Diabetes Management Could Be Replaced By Breathalyzer

XTALKS VITALS NEWS

Parkinson's Disease

In most cases, this is faster and less-invasive than traditional fingerprick glucose meters.

Share this!

December 6, 2016 | by Sarah Hand, M.Sc.

While the amount of acetone present in a patient’s breath is an accurate biomarker for blood glucose concentration, breathalyzer technology was previously not developed enough for clinical use. As a result, diabetics must use a fingerprick device multiple times per day to monitor blood glucose levels.

Now, researchers at Western New England University have developed a way of measuring breath acetone concentration using a cost-effective, portable medical device. In speaking with medGadget, Dr. Ronny Priefer of the university’s Department of Pharmaceutical and Administrative Sciences, and one of the scientists that developed the device, explained how the technology works.

According to Priefer, breath samples are composed primarily of water, with only a small fraction consisting of acetone. If acetone is only present in a few parts per billion, this presents a challenge in accurately quantifying the compound.



While most previous attempts at creating an acetone breathalyzer have applied a method of removing the water from the sample, this is difficult to do without removing the acetone as well. To mediate this issue, Priefer and his colleagues decided to use the water as a sensor activation agent in their medical device.

This new technology applies polymer layers which swell when exposed to humid air in breath samples. This response allows any acetone to penetrate the polymer layers, which triggers the formation of cross-links between alternating layers.

Using spectroscopy, the researchers were able to quantify the amount of cross-linking in the device, allowing them to determine the amount of acetone present in the patient’s sample. The amount of acetone can then be used to establish how much glucose is in the blood.

While the inner workings of the medical device are complex, the test only takes about ten seconds to return a result. In most cases, this is faster and less-invasive than traditional fingerprick glucose meters.

According to the researchers, the technology behind the medical device in inexpensive, which could make it an ideal candidate for applications in clinical practice. So far, the device only exists in a prototype form, however the researchers are planning a clinical trial to test the technology.


Keywords: Diabetes, Glucose Monitor, Disease Management


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.